aluates Reports

$ 0.0

Automative

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Research Report 2024

Published Date: July 2024

Report Code: QYRE-Auto-24N1059

Global Benign Prostatic Hyperplasia BPH Treatment Market Insights and Forecast to 2028

BUY CHAPTERS

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Research Report 2024

Code: QYRE-Auto-24N1059

Report

July 2024

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi

GlaxoSmithKline PLC

Allergan plc

Eli Lilly

Astellas Pharma

Viatris

Abbott

TEVA

Novartis

Merck

Benign Prostatic Hyperplasia (BPH) Treatment Market Size

The global Benign Prostatic Hyperplasia (BPH) Treatment market was valued at US$ 3385 million in 2023 and is anticipated to reach US$ 3817.7 million by 2030, witnessing a CAGR of 2.0% during the forecast period 2024-2030.

Benign Prostatic Hyperplasia (BPH) Treatment Market

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Treatment.

Report Scope

The Benign Prostatic Hyperplasia (BPH) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Benign Prostatic Hyperplasia (BPH) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Benign Prostatic Hyperplasia (BPH) Treatment Market Report

Report Metric	Details
Report Name	Benign Prostatic Hyperplasia (BPH) Treatment Market
Accounted market size in 2023	US$ 3385 million
Forecasted market size in 2030	US$ 3817.7 million
CAGR	2.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Alpha-Blocker Phosphodiesterase Type-5 Inhibitors Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Viatris, Abbott, Allergan, TEVA, Novartis, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Benign Prostatic Hyperplasia (BPH) Treatment Market growing?

Ans: The Benign Prostatic Hyperplasia (BPH) Treatment Market witnessing a CAGR of 2.0% during the forecast period 2024-2030.

What is the Benign Prostatic Hyperplasia (BPH) Treatment Market size in 2030?

Ans: The Benign Prostatic Hyperplasia (BPH) Treatment Market size in 2030 will be US$ 3817.7 million.

Who are the main players in the Benign Prostatic Hyperplasia (BPH) Treatment Market report?

Ans: The main players in the Benign Prostatic Hyperplasia (BPH) Treatment Market are Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Viatris, Abbott, Allergan, TEVA, Novartis, Merck

What are the Application segmentation covered in the Benign Prostatic Hyperplasia (BPH) Treatment Market report?

Ans: The Applications covered in the Benign Prostatic Hyperplasia (BPH) Treatment Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Benign Prostatic Hyperplasia (BPH) Treatment Market report?

Ans: The Types covered in the Benign Prostatic Hyperplasia (BPH) Treatment Market report are Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Alpha-Blocker

1.2.3 Phosphodiesterase Type-5 Inhibitors

1.2.4 Others

1.3 Market by Application

1.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Perspective (2019-2030)

2.2 Benign Prostatic Hyperplasia (BPH) Treatment Growth Trends by Region

2.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Region (2019-2024)

2.2.3 Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Region (2025-2030)

2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Dynamics

2.3.1 Benign Prostatic Hyperplasia (BPH) Treatment Industry Trends

2.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers

2.3.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges

2.3.4 Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue

3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue (2019-2024)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia (BPH) Treatment Revenue

3.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio

3.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2023

3.5 Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Area Served

3.6 Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service

3.7 Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Type

4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Type (2019-2024)

4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2025-2030)

5 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Application

5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Application (2019-2024)

5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)

6.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)

6.4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)

7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)

7.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)

8.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)

9.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)

9.4 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)

10.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Eli Lilly

11.1.1 Eli Lilly Company Detail

11.1.2 Eli Lilly Business Overview

11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.1.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.1.5 Eli Lilly Recent Development

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Detail

11.2.2 GlaxoSmithKline Business Overview

11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.2.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.2.5 GlaxoSmithKline Recent Development

11.3 Astellas Pharma

11.3.1 Astellas Pharma Company Detail

11.3.2 Astellas Pharma Business Overview

11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.3.5 Astellas Pharma Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Detail

11.4.2 Sanofi Business Overview

11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.4.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.4.5 Sanofi Recent Development

11.5 Viatris

11.5.1 Viatris Company Detail

11.5.2 Viatris Business Overview

11.5.3 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.5.4 Viatris Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.5.5 Viatris Recent Development

11.6 Abbott

11.6.1 Abbott Company Detail

11.6.2 Abbott Business Overview

11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.6.4 Abbott Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.6.5 Abbott Recent Development

11.7 Allergan

11.7.1 Allergan Company Detail

11.7.2 Allergan Business Overview

11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.7.5 Allergan Recent Development

11.8 TEVA

11.8.1 TEVA Company Detail

11.8.2 TEVA Business Overview

11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.8.4 TEVA Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.8.5 TEVA Recent Development

11.9 Novartis

11.9.1 Novartis Company Detail

11.9.2 Novartis Business Overview

11.9.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.9.4 Novartis Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.9.5 Novartis Recent Development

11.10 Merck

11.10.1 Merck Company Detail

11.10.2 Merck Business Overview

11.10.3 Merck Benign Prostatic Hyperplasia (BPH) Treatment Introduction

11.10.4 Merck Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

11.10.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Sanofi

GlaxoSmithKline PLC

Allergan plc

Eli Lilly

Astellas Pharma

Viatris

Abbott

TEVA

Novartis

Merck

List of Tables

Table 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Alpha-Blocker

Table 3. Key Players of Phosphodiesterase Type-5 Inhibitors

Table 4. Key Players of Others

Table 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2019-2024)

Table 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2025-2030)

Table 11. Benign Prostatic Hyperplasia (BPH) Treatment Market Trends

Table 12. Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers

Table 13. Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges

Table 14. Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints

Table 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players (2019-2024)

Table 17. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2023)

Table 18. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Treatment Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service

Table 22. Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2019-2024)

Table 26. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2025-2030)

Table 28. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2019-2024)

Table 30. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2025-2030)

Table 32. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 47. Eli Lilly Company Detail

Table 48. Eli Lilly Business Overview

Table 49. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 50. Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 51. Eli Lilly Recent Development

Table 52. GlaxoSmithKline Company Detail

Table 53. GlaxoSmithKline Business Overview

Table 54. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 55. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 56. GlaxoSmithKline Recent Development

Table 57. Astellas Pharma Company Detail

Table 58. Astellas Pharma Business Overview

Table 59. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 60. Astellas Pharma Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 61. Astellas Pharma Recent Development

Table 62. Sanofi Company Detail

Table 63. Sanofi Business Overview

Table 64. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 65. Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 66. Sanofi Recent Development

Table 67. Viatris Company Detail

Table 68. Viatris Business Overview

Table 69. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 70. Viatris Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 71. Viatris Recent Development

Table 72. Abbott Company Detail

Table 73. Abbott Business Overview

Table 74. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 75. Abbott Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 76. Abbott Recent Development

Table 77. Allergan Company Detail

Table 78. Allergan Business Overview

Table 79. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 80. Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 81. Allergan Recent Development

Table 82. TEVA Company Detail

Table 83. TEVA Business Overview

Table 84. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 85. TEVA Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 86. TEVA Recent Development

Table 87. Novartis Company Detail

Table 88. Novartis Business Overview

Table 89. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 90. Novartis Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 91. Novartis Recent Development

Table 92. Merck Company Detail

Table 93. Merck Business Overview

Table 94. Merck Benign Prostatic Hyperplasia (BPH) Treatment Product

Table 95. Merck Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)

Table 96. Merck Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type: 2023 VS 2030

Figure 3. Alpha-Blocker Features

Figure 4. Phosphodiesterase Type-5 Inhibitors Features

Figure 5. Others Features

Figure 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2023 VS 2030

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Online Pharmacies Case Studies

Figure 11. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered

Figure 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region: 2023 VS 2030

Figure 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players in 2023

Figure 16. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2023

Figure 18. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)

Figure 20. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)

Figure 24. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2019-2030)

Figure 32. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)

Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)

Figure 44. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Eli Lilly Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 47. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 48. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 49. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 50. Viatris Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 51. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 52. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 53. TEVA Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 54. Novartis Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 55. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Benign Prostatic Hypertrophy Medication Market Research Report 2024

Benign Prostatic Hyperplasia BPH Laser Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Benign Prostatic Hyperplasia BPH Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Drugs for Benign Prostatic Hyperplasia Market Research Report 2025

Global Benign Prostatic Hyperplasia BPH Drugs Market Insights Forecast to 2030

Laser Benign Prostatic Hyperplasia BPH Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Benign Prostatic Hyperplasia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Benign Prostatic Hyperplasia BPH Treatment Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Benign Prostate Hyperplasia Drugs Market Insights Forecast to 2030

Global Transurethral Resection Of The Prostate Market Research Report 2024

Benign Prostatic Hyperplasia Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Men s Urinary Incontinence Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Benign Prostatic Hyperplasia Equipment Market Research Report 2025

Benign Prostatic Hyperplasia Treatment Equipments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prostate Cancer Diagnostics Market Research Report 2025

Global Prostatic Arterial Embolization PAE Market Insights Forecast to 2030

Global Tamsulosin Market Insights Forecast to 2030

Transurethral Prostatic Resection Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Benign Prostatic Hyperplasia Treatment Market Insights Forecast to 2030

RELATED REPORTS

Global Prostate Cancer Therapeutics Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5R13263

Thu Sep 04 00:00:00 UTC 2025

Add to Cart

Global Prostate Specific Antigen Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-36E7077

Tue Sep 02 00:00:00 UTC 2025

Add to Cart

Global Prostate Cancer Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-1P7758

Sat Aug 30 00:00:00 UTC 2025

Add to Cart

Global Urological Cancer Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39L3749

Sat Aug 30 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions